| |
Cut-off |
Sensitivity
(%) |
Specificity
(%) |
PPV
(%) |
NPV
(%) |
| All samples |
|
|
|
|
|
| AFP-L3 |
4.5% |
70.0 |
92.5 |
72.4 |
91.6 |
| DCP |
0.57 |
53.3 |
98.1 |
88.9 |
88.1 |
| AFP-L3 + DCP |
|
83.3 |
91.3 |
73.5 |
95.1 |
| AFP <20 ng/mL (HCC: n=16, Control: n=102) |
| AFP-L3 |
4.5% |
50.0 |
94.1 |
57.1 |
92.3 |
| DCP |
0.57 |
43.8 |
100.0 |
100.0 |
91.9 |
| AFP-L3 + DCP |
|
75.0 |
94.1 |
66.7 |
96.0 |
The clinical sensitivities would be significantly improved by using the optimal cutoffs
derived from this study data set and further increased by combining all three
biomarkers. |
